Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Hernández MV[au]:

Safety profile of biological therapies for treating rheumatoid arthritis. Cañete JD et al. Expert Opin Biol Ther. (2017)

Advanced Neuroimaging of Cerebral Small Vessel Disease. Blair GW et al. Curr Treat Options Cardiovasc Med. (2017)

Human subcortical brain asymmetries in 15,847 people worldwide reveal effects of age and sex. Guadalupe T et al. Brain Imaging Behav. (2017)

Search results

Items: 1 to 50 of 103

1.

SER recommendations on the use of biological drugs in primary Sjögren's syndrome.

Andréu Sánchez JL, Fernández Castro M, Del Campo Fontecha PD, Corominas H, Narváez García FJ, Gómez de Salazar JR, Rua-Figueroa Í, Abad Hernández MÁ, Álvarez Rivas MN, Montes JDP, Francisco Hernández FM, Gantes Pedraza MÁ, Greco Merino MG, Hernández MV, Navarro Compán MV, Solarte JAP, Romero Bueno FI, Park HS, Sivera Mascaró F.

Reumatol Clin. 2019 Jan 23. pii: S1699-258X(18)30260-2. doi: 10.1016/j.reuma.2018.10.014. [Epub ahead of print] English, Spanish.

2.

Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.

Vegas-Revenga N, Calvo-Río V, Mesquida M, Adán A, Hernández MV, Beltrán E, Valls Pascual E, Díaz-Valle D, Díaz-Cordovés G, Hernandez-Garfella M, Martínez-Costa L, Calvo I, Atanes A, Linares LF, Modesto C, González-Vela C, Demetrio-Pablo R, Aurrecoechea E, Cordero M, Domínguez-Casas LC, Atienza-Mateo B, Martín-Varillas JL, Loricera J, Palmou-Fontana N, Hernández JL, González-Gay MA, Blanco R.

Am J Ophthalmol. 2019 Apr;200:85-94. doi: 10.1016/j.ajo.2018.12.019. Epub 2019 Jan 17.

PMID:
30660771
3.

Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.

Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.

Arthritis Res Ther. 2018 Dec 13;20(1):275. doi: 10.1186/s13075-018-1764-z.

4.

Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.

Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, Martin-Domenech R, Del Pino-Montes J, Manrique S, Castro-Villegas MC, Ruiz-Montesinos D, Sanchez-Alonso F, Diaz-Gonzalez F, Cea-Calvo L, Gómez-Reino JJ; BIOBADASER Study Group.

Rheumatol Int. 2019 Mar;39(3):509-515. doi: 10.1007/s00296-018-4177-z. Epub 2018 Oct 24.

PMID:
30353269
5.

Diagnosis and Integrated Management of Fruit Rot in Cucurbita argyrosperma, Caused by Sclerotium rolfsii.

Nájera JFD, Castellanos JS, Hernández MV, Serna SA, Gómez OGA, Verduzco CV, Ramos MA.

Plant Pathol J. 2018 Jun;34(3):171-181. doi: 10.5423/PPJ.OA.08.2017.0185. Epub 2018 Jun 1.

6.

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.

PMID:
29730637
7.

Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.

Martín-Varillas JL, Calvo-Río V, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Garfella MH, Pascual EV, Martínez-Costa L, Sellas-Fernández A, Cordero-Coma M, Díaz-Llopis M, Gallego R, Salom D, Ortego N, García-Serrano JL, Callejas-Rubio JL, Herreras JM, García-Aparicio Á, Maíz O, Blanco A, Torre I, Díaz-Valle D, Pato E, Aurrecoechea E, Caracuel MA, Gamero F, Minguez E, Carrasco-Cubero C, Olive A, Vázquez J, Ruiz-Moreno O, Manero J, Muñoz-Fernández S, Martinez MG, Rubio-Romero E, Toyos-Sáenz de Miera FJ, López Longo FJ, Nolla JM, Revenga M, González-Vela C, Loricera J, Atienza-Mateo B, Demetrio-Pablo R, Hernández JL, González-Gay MA, Blanco R.

Ophthalmology. 2018 Sep;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020. Epub 2018 Mar 27. Erratum in: Ophthalmology. 2019 Jan;126(1):177.

PMID:
29602570
8.

Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review.

Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, Fernández-Díaz C, Mesquida M, Adán A, Hernández MV, Cordero-Coma M, Maiz Alonso O, Díaz-Valle D, Fernández-Cid C, Ruiz-Moreno O, Hernández JL, González-Gay MA, Blanco R.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):652-657. Epub 2017 Dec 15. Review.

9.

The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.

Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H, Sanmarti R, Zamora C, Cantó E, Vidal S.

Semin Arthritis Rheum. 2018 Jun;47(6):757-764. doi: 10.1016/j.semarthrit.2017.10.022. Epub 2017 Nov 20.

PMID:
29157669
10.

Triggers of the Postural Display of Courtship in Drosophila persimilis Flies.

Hernández MV, Fabre CCG.

J Insect Behav. 2017;30(5):582-594. doi: 10.1007/s10905-017-9641-1. Epub 2017 Oct 18.

11.

The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

Rodríguez PC, Prada DM, Moreno E, Aira LE, Molinero C, López AM, Gómez JA, Hernández IM, Martínez JP, Reyes Y, Milera JM, Hernández MV, Torres R, Avila Y, Barrese Y, Viada C, Montero E, Hernández P.

Clin Exp Immunol. 2018 Feb;191(2):229-239. doi: 10.1111/cei.13061. Epub 2017 Nov 16.

12.

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.

Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J.

Ann Rheum Dis. 2017 Dec;76(12):2025-2030. doi: 10.1136/annrheumdis-2017-211623. Epub 2017 Aug 19.

13.

Safety profile of biological therapies for treating rheumatoid arthritis.

Cañete JD, Hernández MV, Sanmartí R.

Expert Opin Biol Ther. 2017 Sep;17(9):1089-1103. doi: 10.1080/14712598.2017.1346078. Epub 2017 Jul 17. Review.

PMID:
28657381
14.

Advanced Neuroimaging of Cerebral Small Vessel Disease.

Blair GW, Hernandez MV, Thrippleton MJ, Doubal FN, Wardlaw JM.

Curr Treat Options Cardiovasc Med. 2017 Jul;19(7):56. doi: 10.1007/s11936-017-0555-1. Review.

15.

Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.

Cabrera-Villalba S, Gomara MJ, Cañete JD, Ramírez J, Salvador G, Ruiz-Esquide V, Hernández MV, Inciarte-Mundo J, Haro I, Sanmartí R.

Arthritis Res Ther. 2017 Jun 15;19(1):141. doi: 10.1186/s13075-017-1329-6.

16.

Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.

Ramírez J, Narváez JA, Ruiz-Esquide V, Hernández-Gañán J, Cuervo A, Inciarte-Mundo J, Hernández MV, Sampayo-Cordero M, Pablos JL, Sanmartí R, Cañete JD.

Semin Arthritis Rheum. 2017 Dec;47(3):303-309. doi: 10.1016/j.semarthrit.2017.04.007. Epub 2017 May 1.

PMID:
28549731
17.

TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.

Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, Sainz de la Maza M, Adán A.

Retina. 2018 Jul;38(7):1361-1370. doi: 10.1097/IAE.0000000000001690.

PMID:
28520640
18.

Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: time for a new approach?

Acebes C, Andreu JL, Balsa A, Batlle E, de Toro-Santos J, García Llorente F, Hernández MV, Fernández-Gutiérrez B, Hidalgo-Calleja C, Mayordomo L, Naredo E, Narváez FJ, Ortiz AM, Pablos JL, Pérez-Sandoval T, Rodríguez-Lozano C, Sánchez-Pernaute O, Usón J, Negrón JB, Loza E, Carmona L, Gómez Castro S, Montoro Alvarez M.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):816-822. Epub 2017 May 8.

PMID:
28516881
19.

Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice.

González C, Curbelo Rodríguez R, Torre-Alonso JC, Collantes E, Castañeda S, Hernández MV, Urruticoechea-Arana A, Nieto-González JC, García J, Abad MÁ, Ramírez J, Suárez C, Dalmau R, Martín-Arranz MD, León L, Hermosa JC, Obaya JC, Otón T, Carmona L.

Reumatol Clin. 2018 Nov - Dec;14(6):346-359. doi: 10.1016/j.reuma.2017.03.011. Epub 2017 Apr 29. English, Spanish.

20.

Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.

Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordström D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernández MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R.

J Rheumatol. 2017 Feb;44(2):162-169. doi: 10.3899/jrheum.160460. Epub 2017 Jan 15.

PMID:
28089978
21.

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A.

Clin Rheumatol. 2017 Apr;36(4):773-779. doi: 10.1007/s10067-016-3505-5. Epub 2016 Dec 14.

PMID:
27966068
22.

Development of an activity disease score in patients with uveitis (UVEDAI).

Pato E, Martin-Martinez MA, Castelló A, Méndez-Fernandez R, Muñoz-Fernández S, Cordero-Coma M, Martinez-Costa L, Valls E, Reyes M, Francisco F, Esteban M, Fonollosa A, Sanchez-Alonso F, Fernández-Espartero C, Diaz-Valle T, Carrasco JM, Beltran-Catalán E, Hernández-Garfella M, Hernández MV, Pelegrin L, Blanco R, Diaz-Valle D.

Rheumatol Int. 2017 Apr;37(4):647-656. doi: 10.1007/s00296-016-3593-1. Epub 2016 Nov 4.

23.
24.

The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.

Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, Cordero-Coma M, García-Aparicio ÁM, Valls Pascual E, Martínez-Costa L, Hernández MV, Hernandez Garfella M, González-Vela MC, Pina T, Palmou-Fontana N, Loricera J, Hernández JL, González-Gay MA.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):S34-S40. Epub 2016 Apr 7.

PMID:
27054359
25.

Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.

Ramírez J, Inciarte-Mundo J, Cuervo A, Ruiz-Esquide V, Hernández MV, Sanmartí R, Cañete JD.

Clin Exp Rheumatol. 2017 Jan-Feb;35(1):74-79. Epub 2016 Oct 7.

PMID:
27749227
26.

Human subcortical brain asymmetries in 15,847 people worldwide reveal effects of age and sex.

Guadalupe T, Mathias SR, vanErp TGM, Whelan CD, Zwiers MP, Abe Y, Abramovic L, Agartz I, Andreassen OA, Arias-Vásquez A, Aribisala BS, Armstrong NJ, Arolt V, Artiges E, Ayesa-Arriola R, Baboyan VG, Banaschewski T, Barker G, Bastin ME, Baune BT, Blangero J, Bokde ALW, Boedhoe PSW, Bose A, Brem S, Brodaty H, Bromberg U, Brooks S, Büchel C, Buitelaar J, Calhoun VD, Cannon DM, Cattrell A, Cheng Y, Conrod PJ, Conzelmann A, Corvin A, Crespo-Facorro B, Crivello F, Dannlowski U, de Zubicaray GI, de Zwarte SMC, Deary IJ, Desrivières S, Doan NT, Donohoe G, Dørum ES, Ehrlich S, Espeseth T, Fernández G, Flor H, Fouche JP, Frouin V, Fukunaga M, Gallinat J, Garavan H, Gill M, Suarez AG, Gowland P, Grabe HJ, Grotegerd D, Gruber O, Hagenaars S, Hashimoto R, Hauser TU, Heinz A, Hibar DP, Hoekstra PJ, Hoogman M, Howells FM, Hu H, Hulshoff Pol HE, Huyser C, Ittermann B, Jahanshad N, Jönsson EG, Jurk S, Kahn RS, Kelly S, Kraemer B, Kugel H, Kwon JS, Lemaitre H, Lesch KP, Lochner C, Luciano M, Marquand AF, Martin NG, Martínez-Zalacaín I, Martinot JL, Mataix-Cols D, Mather K, McDonald C, McMahon KL, Medland SE, Menchón JM, Morris DW, Mothersill O, Maniega SM, Mwangi B, Nakamae T, Nakao T, Narayanaswaamy JC, Nees F, Nordvik JE, Onnink AMH, Opel N, Ophoff R, Paillère Martinot ML, Papadopoulos Orfanos D, Pauli P, Paus T, Poustka L, Reddy JY, Renteria ME, Roiz-Santiáñez R, Roos A, Royle NA, Sachdev P, Sánchez-Juan P, Schmaal L, Schumann G, Shumskaya E, Smolka MN, Soares JC, Soriano-Mas C, Stein DJ, Strike LT, Toro R, Turner JA, Tzourio-Mazoyer N, Uhlmann A, Hernández MV, van den Heuvel OA, van der Meer D, van Haren NEM, Veltman DJ, Venkatasubramanian G, Vetter NC, Vuletic D, Walitza S, Walter H, Walton E, Wang Z, Wardlaw J, Wen W, Westlye LT, Whelan R, Wittfeld K, Wolfers T, Wright MJ, Xu J, Xu X, Yun JY, Zhao J, Franke B, Thompson PM, Glahn DC, Mazoyer B, Fisher SE, Francks C.

Brain Imaging Behav. 2017 Oct;11(5):1497-1514. doi: 10.1007/s11682-016-9629-z.

27.

Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.

Calvo-Río V, Santos-Gómez M, Calvo I, González-Fernández MI, López-Montesinos B, Mesquida M, Adán A, Hernández MV, Maíz O, Atanes A, Bravo B, Modesto C, Díaz-Cordovés G, Palmou-Fontana N, Loricera J, González-Vela MC, Demetrio-Pablo R, Hernández JL, González-Gay MA, Blanco R.

Arthritis Rheumatol. 2017 Mar;69(3):668-675. doi: 10.1002/art.39940.

28.

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.

Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A.

EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024. Epub 2016 Aug 18.

29.

Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.

Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.

Arthritis Res Ther. 2016 Jul 8;18(1):160. doi: 10.1186/s13075-016-1032-z.

30.

Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding.

Martínez López JA, García Vivar ML, Cáliz R, Freire M, Galindo M, Hernández MV, López Longo FJ, Martínez Taboada V, Pego Reigosa JM, Rubio E, Trujillo E, Vela-Casasempere P.

Reumatol Clin. 2017 Sep - Oct;13(5):264-281. doi: 10.1016/j.reuma.2016.05.003. Epub 2016 Jun 17. English, Spanish.

31.

Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.

García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D; BIOBADADERM and BIOBADASER study groups.

Br J Dermatol. 2017 Mar;176(3):643-649. doi: 10.1111/bjd.14776. Epub 2016 Oct 3.

PMID:
27258623
32.

The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.

Hernández MV, Sanmartí R, Cañete JD.

Expert Opin Drug Saf. 2016 May;15(5):613-24. doi: 10.1517/14740338.2016.1160054. Epub 2016 Mar 21. Review.

PMID:
26927029
33.

Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.

Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A.

Arthritis Rheumatol. 2016 Jun;68(6):1346-52. doi: 10.1002/art.39595.

34.

Progression of White Matter Disease and Cortical Thinning Are Not Related in Older Community-Dwelling Subjects.

Dickie DA, Karama S, Ritchie SJ, Cox SR, Sakka E, Royle NA, Aribisala BS, Hernández MV, Maniega SM, Pattie A, Corley J, Starr JM, Bastin ME, Evans AC, Deary IJ, Wardlaw JM.

Stroke. 2016 Feb;47(2):410-6. doi: 10.1161/STROKEAHA.115.011229. Epub 2015 Dec 22.

35.

Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.

Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, Velloso-Feijoo ML, Narváez J, Jiménez-Moleón I, Maiz-Alonso O, Ordóñez C, Bernal JA, Hernández MV, Sifuentes-Giraldo WA, Gómez-Arango C, Galíndez-Agirregoikoa E, Blanco-Madrigal J, Ortiz-Santamaria V, del Blanco-Barnusell J, De Dios JR, Moreno M, Fiter J, de los Riscos M, Carreira P, Rodriguez-Valls MJ, González-Vela MC, Calvo-Río V, Loricera J, Palmou-Fontana N, Pina T, Llorca J, González-Gay MA.

Medicine (Baltimore). 2015 Sep;94(39):e1554. doi: 10.1097/MD.0000000000001554.

36.

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.

Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, Canhao H, Chatzidionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PL, van Vollenhoven R, Kvien TK.

Ann Rheum Dis. 2016 Jul;75(7):1336-42. doi: 10.1136/annrheumdis-2015-207760. Epub 2015 Sep 15.

37.

Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.

Narváez J, Magallares B, Díaz Torné C, Hernández MV, Reina D, Corominas H, Sanmartí R, LLobet JM, Rodriguez de la Serna A, Nolla JM.

Semin Arthritis Rheum. 2016 Feb;45(4):386-90. doi: 10.1016/j.semarthrit.2015.07.001. Epub 2015 Jul 6.

PMID:
26254548
38.

Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.

Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba SR, Ramirez J, Yagüe J, Sanmarti R.

Rheumatology (Oxford). 2015 Dec;54(12):2239-43. doi: 10.1093/rheumatology/kev251. Epub 2015 Aug 4.

PMID:
26242859
39.

IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients.

Ortiz MA, Diaz-Torné C, Hernández MV, Reina D, de la Fuente D, Castellví I, Moya P, Ruiz JM, Corominas H, Zamora C, Cantó E, Sanmartí R, Juarez C, Vidal S.

Clin Immunol. 2015 Jun;158(2):174-82. doi: 10.1016/j.clim.2015.03.025. Epub 2015 Apr 3.

PMID:
25847223
40.

Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.

Narváez J, Díaz-Torné C, Magallares B, Hernández MV, Reina D, Corominas H, Sanmartí R, de la Serna AR, Llobet JM, Nolla JM.

PLoS One. 2015 Apr 1;10(4):e0123392. doi: 10.1371/journal.pone.0123392. eCollection 2015.

41.

Looking beyond Fear and Extinction Learning: Considering Novel Treatment Targets for Anxiety.

Britton JC, Evans TC, Hernandez MV.

Curr Behav Neurosci Rep. 2014 Sep;1(3):134-143.

42.

Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization.

Llorenç V, Mesquida M, Sainz de la Maza M, Keller J, Molins B, Espinosa G, Hernandez MV, Gonzalez-Martín J, Adán A.

Acta Ophthalmol. 2015 Sep;93(6):561-7. doi: 10.1111/aos.12675. Epub 2015 Feb 15.

43.

Is there subclinical synovitis in patients with palindromic rheumatism in the intercritical period? a clinical and ultrasonographic study according to anticitrullinated protein antibody status.

Cabrera-Villalba S, Ramirez J, Salvador G, Ruiz-Esquide V, Hernández MV, Inciarte-Mundo J, Gómez-Puerta JA, Cañete JD, Sanmarti R.

J Rheumatol. 2014 Aug;41(8):1650-5. doi: 10.3899/jrheum.131545. Epub 2014 Jul 15.

PMID:
25028368
44.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
45.

Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet's disease.

Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Hernandez MV, Espinosa G, Adán A.

Mediators Inflamm. 2014;2014:396204. doi: 10.1155/2014/396204. Epub 2014 Jun 8.

46.

Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.

Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olivé A, Castañeda S, Gallego Flores A, Hernández MV, Mata C, Ros Vilamajo I, Sifuentes Giraldo WA, Caracuel MA, Freire M, Gómez Arango C, Llobet J, Manrique Arija S, Marras C, Moll-Tuduri C, Plasencia-Rodriguez C, Roselló R, Urruticoechea A, Velloso-Feijoo ML, Del Blanco J, González-Vela MC, Rueda-Gotor J, Pina T, Loricera J, González-Gay MA.

Arthritis Rheumatol. 2014 Jun;66(6):1659-65. doi: 10.1002/art.38398.

47.

Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients.

Gómez-Puerta JA, Celis R, Hernández MV, Ruiz-Esquide V, Ramírez J, Haro I, Cañete JD, Sanmartí R.

Arthritis Res Ther. 2013 Nov 7;15(6):R182. doi: 10.1186/ar4372.

48.

Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers.

Ramírez J, Ruíz-Esquide V, Pomés I, Celis R, Cuervo A, Hernández MV, Pomés J, Pablos JL, Sanmartí R, Cañete JD.

Arthritis Res Ther. 2014 Jan 8;16(1):R5. doi: 10.1186/ar4431.

49.

APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients.

Barberá A, Lorenzo N, Garrido G, Mazola Y, Falcón V, Torres AM, Hernández MI, Hernández MV, Margry B, de Groot AM, van Roon J, van der Zee R, Broere F, van Eden W, Padrón G, Domínguez Mdel C.

Int Immunopharmacol. 2013 Dec;17(4):1075-83. doi: 10.1016/j.intimp.2013.10.010. Epub 2013 Oct 29.

PMID:
24177275
50.

Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.

Hernández MV, Sanmartí R, Cañete JD, Descalzo MA, Alsina M, Carmona L, Gomez-Reino JJ; BIOBADASER 2.0 Study Group.

Arthritis Care Res (Hoboken). 2013 Dec;65(12):2024-31. doi: 10.1002/acr.22096.

Supplemental Content

Loading ...
Support Center